Nacionale covers research into whether GLP-1 drugs have effects reaching into criminal justice outcomes and how steadily people stay employed.
Recap by typeshit. Full story at Nacionale.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
McGill researchers pooled data on 25,816 adults. Amycretin reached about 23.9% placebo-subtracted loss and retatrutide about 22.1%, though trials differed.
Lawmaker data counted 5,973 gallstone and 1,264 pancreatitis cases after prescriptions. Endocrinologists say rapid weight loss and glucose shifts may explain some.
Loading…